RecruitingNot ApplicableNCT03772275
Utility of Some Novel Biomarkers of Patients With Chronic Heart Failure
Clinical and Economical Study Evaluating the Utility of Some Novel Biomarkers of Patients With Chronic Heart Failure
Sponsor
Sherief Abd-Elsalam
Enrollment
60 participants
Start Date
Oct 1, 2018
Study Type
INTERVENTIONAL
Conditions
Summary
Clinical and Economic study of some new biomarkers in chronic heart failure.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria1
- NYHA-Class II-IV
Exclusion Criteria1
- Liver or renal dysfunction. --DM
Interventions
DIAGNOSTIC_TESTNew york Heart Association Class II-IV
New york Heart Association Class II-IV " study of markers"
DIAGNOSTIC_TESTNew york Heart Association Class I
New york Heart Association Class I
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03772275
Related Trials
Mind Your Heart-II
NCT054311921 location
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288652 locations
ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies
NCT071917301 location
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370641 locations
Timing of Coronary Angiography in NSTEMI Complicated by Acute HF
NCT0700216420 locations